When is the next results date for Meghmani Organi.?

No Upcoming Board Meetings

Has Meghmani Organi. declared dividend?

Yes, Meghmani Organics Ltd has declared a 140% dividend, amounting to ₹1.4 per share, with an ex-date of June 20, 2023. However, the total returns over various periods have shown mixed performance, with a lack of dividend yield indicating minimal impact on overall returns.

Meghmani Organics Ltd has declared a 140% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 140%<BR>- Amount per share: 1.4<BR>- Ex-date: 20 Jun 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.3%, the dividend return was 0%, resulting in a total return of -4.3%.<BR><BR>Over the past year, the price return was 14.07%, the dividend return was 0%, leading to a total return of 14.07%.<BR><BR>For the 2-year period, the price return was 4.44%, the dividend return was 1.59%, resulting in a total return of 6.03%.<BR><BR>In the 3-year period, the price return was -30.83%, the dividend return was 1.26%, leading to a total return of -29.57%.<BR><BR>Over the last 4 years, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Meghmani Organics Ltd has declared a significant dividend, the total returns over various periods show mixed performance, particularly with negative returns in the short and long term. The lack of dividend yield indicates that the dividend has not significantly impacted the overall returns.

Who are the peers of the Meghmani Organi.?

Peers of Meghmani Organics include P I Industries, UPL, Bayer CropSci, and Dhanuka Agritech, among others. Meghmani has below-average management risk and growth, with a 1-year return of 12.29%.

Peers: The peers of Meghmani Organi. are P I Industries, UPL, Bayer CropSci., Sumitomo Chemi., Dhanuka Agritech, Astec Lifescienc, Punjab Chemicals, Heranba Inds, Dharmaj Crop, and Shivalik Rasayan.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bayer CropSci. and Dhanuka Agritech, while Good management risk is found at P I Industries and Sumitomo Chemi. Average management risk is seen at UPL, Punjab Chemicals, Heranba Inds, and Dharmaj Crop, while Below Average management risk is noted for Meghmani Organi., Astec Lifescienc, and Shivalik Rasayan. Growth is Excellent at Dhanuka Agritech, while Excellent growth is found at P I Industries. Below Average growth is observed at UPL, Bayer CropSci., Sumitomo Chemi., Meghmani Organi., Astec Lifescienc, and the rest. Average growth is noted for Dharmaj Crop, while the rest have Below Average growth. Capital Structure is Excellent at Bayer CropSci., Sumitomo Chemi., and Dhanuka Agritech, while Good capital structure is found at Punjab Chemicals and Heranba Inds. Average capital structure is noted for Meghmani Organi. and Astec Lifescienc, while the rest have Below Average capital structure.<BR><BR>Return Snapshot: Dhanuka Agritech has the highest 1-year return at 32.65%, while Astec Lifescienc has the lowest at -35.47%. Meghmani Organi.'s 1-year return is 12.29%, which is higher than Astec Lifescienc but lower than Dhanuka Agritech. Additionally, Astec Lifescienc, Heranba Inds, and Shivalik Rasayan have negative six-month returns.

Who are in the management team of Meghmani Organi.?

As of March 2022, the management team of Meghmani Organi includes Executive Chairman Jayanti M Patel, Managing Directors Ashish N Soparkar and Natwarlal M Patel, and several other directors and officers responsible for the company's operations and strategy.

As of March 2022, the management team of Meghmani Organi includes:<BR><BR>1. Jayanti M Patel - Executive Chairman<BR>2. Ashish N Soparkar - Managing Director<BR>3. Natwarlal M Patel - Managing Director<BR>4. Ramesh M Patel - Executive Director<BR>5. Anand I Patel - Executive Director<BR>6. Urvashi Dhirubhai Shah - Non-Executive & Independent Director<BR>7. Manubhai Khodidas Patel - Non-Executive & Independent Director<BR>8. Ganapati D Yadav - Non-Executive & Independent Director<BR>9. Jayesh Patel - Company Secretary & Compliance Officer<BR>10. Varesh Sinha - Independent Director<BR>11. Nikunt Raval - Additional Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Meghmani Organi. do?

Meghmani Organics Ltd manufactures and sells pigment and agrochemical products, classified as a small-cap company with a market cap of INR 2,612 Cr. As of March 2025, it reported net sales of 5,535 Cr and a net profit of 198 Cr.

Overview:<BR>Meghmani Organics Ltd is engaged in the manufacturing and selling of pigment and agrochemical products within the pesticides and agrochemicals industry, classified as a small-cap company.<BR><BR>History:<BR>The company was originally incorporated as 'Meghmani Organochem Limited' on 15 October 2019 and changed its name to "Meghmani Organics Limited" on 3rd August 2021. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 5,535 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 198 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 2,612 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 33<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.53<BR>- Return on Equity: -0.70%<BR>- Price to Book: 1.71<BR><BR>Contact Details:<BR>No Company Details Available. Registrar Address: Not available.

Who are the top shareholders of the Meghmani Organi.?

The top shareholders of Meghmani Organi include promoter Ashishbhai Natawarlal Soparkar with 10.59%, 45 Foreign Institutional Investors holding 1.81%, and public shareholder Gadia Naveen Vishwanath with 1.35%. Individual investors collectively own 37.9% of the shares.

The top shareholders of Meghmani Organi include the promoters, who hold the majority of the shares. The promoter with the highest holding is Ashishbhai Natawarlal Soparkar, who owns 10.59% of the company. Additionally, there are 45 Foreign Institutional Investors (FIIs) holding a combined 1.81% of the shares. The highest public shareholder is Gadia Naveen Vishwanath, with a holding of 1.35%. Individual investors collectively hold 37.9% of the shares.

How big is Meghmani Organi.?

As of 24th July, Meghmani Organics Ltd has a market capitalization of 2,493.00 Cr, with recent net sales of 2,079.74 Cr and a net loss of 10.60 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Meghmani Organics Ltd has a market capitalization of 2,493.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,079.74 Cr. The sum of Net Profit for the same period shows a loss of 10.60 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025. Shareholder's Funds are valued at 1,515.26 Cr, and Total Assets amount to 3,085.41 Cr.

Are Meghmani Organi. latest results good or bad?

Meghmani Organics' latest results show a 6.14% revenue growth, but operating margins fell significantly, and net profit declined 8.91% from the previous quarter, raising concerns about core operational performance and profitability. Overall, the results are mixed, indicating some recovery but significant challenges remain.

Meghmani Organics' latest results present a mixed picture. On one hand, the company reported a revenue growth of 6.14% year-on-year, reaching ₹577.26 crores, which indicates some recovery in demand within the agrochemicals sector. However, this growth was overshadowed by a significant contraction in operating margins, which fell to 9.03% from 10.90% in the previous quarter. <BR><BR>The net profit of ₹11.55 crores, while positive compared to the losses in the same quarter last year, represented an 8.91% decline from the previous quarter. This decline raises concerns, particularly because the profit was heavily reliant on non-operating income, which accounted for over 106% of profit before tax. This dependency suggests that the core operational performance of the company is weak.<BR><BR>Moreover, the elevated tax rate of 55.73% and rising interest expenses further compressed profitability. Overall, while there are signs of revenue growth, the quality of earnings and operational efficiency remain significant concerns, indicating that the results are not entirely favorable.

Is Meghmani Organi. overvalued or undervalued?

As of November 10, 2025, Meghmani Organics is considered undervalued with an attractive valuation grade, a PE ratio of 46.23, and strong growth potential, especially when compared to peers like Sudarshan Chemicals and Kiri Industries, despite its recent underperformance against the Sensex.

As of 10 November 2025, the valuation grade for Meghmani Organics has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, particularly given its PE ratio of 46.23, an EV to EBITDA of 34.63, and a PEG ratio of 0.31, which suggests strong growth potential relative to its price. <BR><BR>In comparison to its peers, Meghmani stands out with a more favorable valuation than Sudarshan Chemicals, which is deemed expensive with a PE of 96.51, and Kiri Industries, which is classified as risky with a PE of 26.11. Additionally, while the stock has underperformed against the Sensex over various periods, including a 1-year decline of 29.12% compared to the Sensex's 5.09% gain, the attractive valuation suggests potential for recovery and growth in the future.

Is Meghmani Organi. technically bullish or bearish?

As of November 14, 2025, Meghmani Organics has a bearish technical stance, indicated by bearish MACD, Bollinger Bands, moving averages, and KST across multiple timeframes, along with significant underperformance compared to the Sensex.

As of 14 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Meghmani Organics is bearish, with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish Bollinger Bands on both weekly and monthly timeframes, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on both weekly and monthly timeframes, while the Dow Theory indicates a mildly bearish outlook on the weekly and monthly. The stock has underperformed significantly compared to the Sensex across multiple timeframes, further supporting the bearish sentiment.

How has been the historical performance of Meghmani Organi.?

Meghmani Organi's historical performance has been volatile, with net sales peaking at 2,552.62 Cr in March 2023 before declining to 2,079.75 Cr by March 2025, alongside a drop in operating profit and ongoing challenges reflected in negative profit after tax of -10.60 Cr in March 2025. Total liabilities increased to 3,085.41 Cr, indicating financial strain despite some recovery in profit before tax.

Answer:<BR>The historical performance of Meghmani Organi shows significant fluctuations in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Meghmani Organi's net sales peaked at 2,552.62 Cr in March 2023 but declined to 2,079.75 Cr by March 2025. The total operating income followed a similar trend, decreasing from 2,552.62 Cr in March 2023 to 2,079.75 Cr in March 2025. The company's operating profit (PBDIT) also saw a decline, reaching 186.62 Cr in March 2025 after a high of 474.75 Cr in March 2022. The profit before tax turned positive again in March 2025 at 9.47 Cr, recovering from a loss of 121.18 Cr in March 2024. However, the profit after tax remained negative at -10.60 Cr in March 2025, indicating ongoing challenges. The company's total liabilities increased from 2,797.61 Cr in March 2022 to 3,085.41 Cr in March 2025, while total assets also rose to 3,085.41 Cr in March 2025. Cash flow from operating activities decreased to 66.00 Cr in March 2025, down from 333.00 Cr in March 2021, reflecting a decline in operational efficiency. Overall, Meghmani Organi's financial performance has been volatile, with notable highs and lows across various metrics.

Should I buy, sell or hold Meghmani Organi.?

Which are the latest news on Meghmani Organi.?

Why is Meghmani Organi. falling/rising?

As of 03-Dec, Meghmani Organics Ltd's stock price is rising to 67.90, indicating a positive shift in investor sentiment after a trend reversal. However, the stock has a long-term return of -30.64% and weak fundamentals, suggesting ongoing challenges ahead.

As of 03-Dec, Meghmani Organics Ltd's stock price is rising, currently at 67.90, reflecting an increase of 1.08 (1.62%). This upward movement follows a trend reversal after four consecutive days of decline. The stock has outperformed its sector by 1% today, indicating a positive shift in investor sentiment. Additionally, there has been a rise in investor participation, with a delivery volume of 2.29 lacs on December 2, which is up by 0.48% compared to the five-day average.<BR><BR>Despite the recent rise, it is important to note that the stock has faced significant challenges over the longer term. Over the past year, it has generated a return of -30.64%, and its performance has been below that of the benchmark indices, such as the Sensex. The company has shown strong financial results in the last five consecutive quarters, with a notable growth in net sales and profit after tax, which may contribute to the current positive sentiment. However, the long-term fundamentals remain weak, with a -18.02% CAGR growth in operating profits over the last five years and a low average return on equity of 6.03%. <BR><BR>In summary, while Meghmani Organics Ltd is experiencing a rise in stock price due to a recent trend reversal and improved investor participation, it continues to face significant long-term challenges that could impact its future performance.